Which chemotherapeutic agent is well known to cause coronary vasospasm?
5-fluorouracil is well known to cause coronary vasospasm. 5-fluorouracil and its orally active prodrug capecitabine are fluoropyrimidines, belonging to the class of antimetabolites used for treatment of malignancies of breast, head and neck tumours and gastrointestinal tumours.
Mechanisms for coronary vasospasm
Endothelial cell damage with cytolysis and denudation
Increased endothelin-1 bioactivity leading to vasoconstriction
When high dose infusions are given, coronary vasospasm with angina, arrhythmia or even sudden death can occur in up to 5% of patients. Vascular toxicity occurs generally within 72 hours of the...
Source: Cardiophile MD - November 13, 2022 Category: Cardiology Authors: Johnson Francis Tags: General Cardiology Source Type: blogs
How to Take Care of Your Eyes as You Age: be aware of GMC: Glaucoma, Macular degeneration, Cataract
FromConsumer Reports:GlaucomaMore than 2 million Americans have glaucoma, but 50% know it. Glaucoma often goes undiagnosed because it causes no symptoms until vision declines, at which point treatment no longer helps.People aged 40-60 should be examined by an optometrist every 3-5 years; those older than 60 need an eye exam every 1-2 years.Many eye doctors screen for glaucoma with tonometry (measures eye pressure) but that ’s not enough. Relying only on intraocular pressure (IOP) when screening for glaucoma could miss up to 50% of all cases. Theexam should also include an ophthalmoscopy, which involves examining your opt...
Source: Clinical Cases and Images - Blog - October 2, 2019 Category: Universities & Medical Training Tags: Ophthalmology Source Type: blogs
Chemotherapeutic agent causing coronary vasospasm – Cardiology MCQ – Answer
Chemotherapeutic agent causing coronary vasospasm – Cardiology MCQ – Answer
Chemotherapeutic agent well known to cause coronary vasospasm:Correct answer: c) 5-fluorouracil
5-fluorouracil and its orally active prodrug capecitabine are fluoropyrimidines, belonging to the class of antimetabolites used for treatment of malignancies of breast, head and neck tumours and gastrointestinal tumours.
Mechanisms for coronary vasospasm
Endothelial cell damage with cytolysis and denudation
Increased endothelin-1 bioactivity leading to vasoconstriction
When high dose infusions are given, coronary vasospasm with angina, arrh...
Source: Cardiophile MD - February 22, 2019 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardiology MCQ DM / DNB Cardiology Entrance Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD
Long list of news in lung cancer
September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort compared with the contr...
Source: The Health Care Blog - January 4, 2019 Category: Consumer Health News Authors: matthew holt Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs
Fake Reform Foisted on Us by Those who Benefit Most from the Current Dysfunction
ConclusionGiridharadas suggested inan interview in New York Magazine,What all that does is create this moral glow. And under the haze created by that glow, they ’re able to create a probable monopoly that has harmed the most sacred thing in America, which is our electoral process, while gutting the other most sacred thing in America, our free press. And they do itunder the cover of changing the world.Unfortunately, he apparently has not come up with what to do about this problem. The best conclusion I can reach derives from the end of areview of his book by Joseph Stiglitz in the New York Times,Democracy and high l...
Source: Health Care Renewal - September 5, 2018 Category: Health Management Tags: conflicts of interest Gates Foundation health care foundations health care reform Johnson and Johnson Robert Wood Johnson Foundation Source Type: blogs
The Skeptical Oncologist
By BISHAL GYAWALI, MD
Why conduct post approval studies at all?
Atezolizumab previously received accelerated approval in second-line metastatic or advanced urothelial cancer based on response rates from a single arm trial. The results of post approval confirmatory phase 3 are now published and demonstrate that atezolizumab did not improve survival versus chemotherapy (11.1 v 10.6 months, HR 0.87, p = 0.41). The concept of accelerated approval is to grant early and conditional approval and access to drugs in diseases of unmet need, and that the decision to fully approve or revoke be made based on results of confirmato...
Source: The Health Care Blog - February 7, 2018 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Source Type: blogs
More on US Healthcare Prices
In a recent post, I showed two drugs that were much more expensive in the United States than elsewhere. One was for rheumatoid arthritis and the other for hepatitis C. Today we get to look at a cancer drug, Avastin, … Continue reading →
The post More on US Healthcare Prices appeared first on PeterUbel.com. (Source: blog.bioethics.net)
Source: blog.bioethics.net - October 5, 2017 Category: Medical Ethics Authors: Peter Ubel Tags: Health Care cancer healthcare costs Peter Ubel syndicated Uncategorized Source Type: blogs
7 Things to Know About Glioblastoma
News recently shocked the nation that Sen. John McCain was diagnosed with an aggressive form of brain cancer called glioblastoma. Dr. Mark Mishra, a radiation oncologist at the University of Maryland Greenebaum Comprehensive Cancer Center and Maryland Proton Treatment Center who specializes in treating brain cancer, tells you 7 things to know about glioblastoma.
How common is glioblastoma?
Glioblastoma is the most common type of primary brain tumor that is diagnosed in adults. There are estimated to be nearly 13,000 patients who will be diagnosed with a glioblastoma annually within the United States.
Why is it so aggr...
Source: Life in a Medical Center - July 21, 2017 Category: Universities & Medical Training Authors: UMMC Tags: Cancer Source Type: blogs
Genentech & Escobar: Using Materiality to Escape False Claims Liability
In constructively bringing an end to a False Claims Act (“FCA”) whistleblower suit alleging Genentech, Inc. (“Genentech”) of defrauding Medicare by way of concealing substantive health care analytics data involving purported side effects of the company’s cancer drug Avastin, the Third Circuit of Appeals in a recent decision determined that the Plaintiff in this matter had failed to demonstrate that any noncompliance had an impact on government payments. Specifically, the Court applied the prevailing standard in Escobar that an FCA lawsuit must demonstrate that any misrepresentation is “material” to the govern...
Source: Policy and Medicine - June 26, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Genentech Beats FCA Suit, Thanks to Escobar
On Monday, May 1, 2017, the United States Court of Appeals for the Third Circuit stopped a False Claims Act suit that accused Genentech Inc. of defrauding Medicare by concealing certain side effects of its cancer drug Avastin, stating that the whistleblower did not show that failing to report such safety information was relevant to government reimbursement for medication.
Prior to filing his qui tam suit, The relator, Gerasimos Petratos, a prior global head of health care data analytics for Genentech, allegedly recommended implementing a different database that he believed would more accurately reflect the drug’s side e...
Source: Policy and Medicine - May 4, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Genentech Beats FCA Suit, Thanks to Escobar
On Monday, May 1, 2017, the United States Court of Appeals for the Third Circuit stopped a False Claims Act suit that accused Genentech Inc. of defrauding Medicare by concealing certain side effects of its cancer drug Avastin, stating that the whistleblower did not show that failing to report such safety information was relevant to government reimbursement for medication.
Prior to filing his qui tam suit, The relator, Gerasimos Petratos, a prior global head of health care data analytics for Genentech, allegedly recommended implementing a different database that he believed would more accurately reflect the drug’s side e...
Source: Policy and Medicine - May 4, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Value-Based Pricing For Pharmaceuticals In The Trump Administration
Everyone seems to agree: Drug prices are too damn high. Scandalous prices for new drugs and enormous price hikes on old drugs have focused public ire on the pharmaceutical industry. A bipartisan consensus has emerged that something must be done to tackle drug prices.
There’s less consensus, however, about what that something ought to be. Allowing Medicare to negotiate drug prices is one popular possibility; outright price controls are also under discussion. But with Republicans in control of both Congress and the White House, neither appears to be on the policy agenda. But one market-friendly alternative, “value-based ...
Source: Health Affairs Blog - April 27, 2017 Category: Health Management Authors: Rachel Sachs, Nicholas Bagley and Darius Lakdawalla Tags: Costs and Spending Drugs and Medical Innovation Medicaid and CHIP Medicare Payment Policy Centers for Medicare and Medicaid Services drug pricing outcome-based pricing valued-based pricing Source Type: blogs
Overcoming Challenges Of Outcomes-Based Contracting For Pharmaceuticals: Early Lessons From The Genentech – Priority Health Pilot
Conclusion
Outcomes-based agreements are a natural extension of a health care delivery-and-reimbursement environment that is moving toward value. With provider organizations taking increasing accountability for both costs and outcomes, it is becoming incumbent upon manufacturers to demonstrate the economic, clinical, and quality-of-life benefits of their medicines. The pilot described here was successful in that Genentech and Priority Health both learned how to overcome clinical, operational, and contractual challenges and demonstrated that this type of agreement is feasible. Genentech and Priority Health believe pilots li...
Source: Health Affairs Blog - April 3, 2017 Category: Health Management Authors: John Fox and Marc Watrous Tags: Costs and Spending Drugs and Medical Innovation Payment Policy Outcomes-based agreements Source Type: blogs
